

- of Smad4, a TGF-beta signaling molecule, in oral squamous cell carcinoma. *J Oral Sci* 2006; 48: 105-9.
22. Kloth JN, Kenter GG, Spijker HS, *et al.* Expression of Smad2 and Smad4 in cervical cancer: absent nuclear Smad4 expression correlates with poor survival. *Mod Pathol* 2008; 21: 866-75.
23. Koorstra JB, Hustinx SR, Offerhaus GJ, Maitra A. Pancreatic carcinogenesis. *Pancreatol* 2008; 8: 110-25.
24. Massagué J. G1 cell-cycle control and cancer. *Nature* 2004; 432: 298-306.
25. Wakefield LM, Roberts AB. TGF-beta signaling: positive and negative effects on tumorigenesis. *Curr Opin Genet Dev* 2002; 12: 22-9.
26. Qiu W, Schönleben F, Li X, Su GH. Disruption of transforming growth factor beta-Smad signaling pathway in head and neck squamous cell carcinoma as evidenced by mutations of SMAD2 and SMAD4. *Cancer Lett* 2007; 245: 163-70.
27. Wang LH, Kim SH, Lee JH, *et al.* Inactivation of SMAD4 tumor suppressor gene during gastric carcinoma progression. *Clin Cancer Res* 2007; 13: 102-10.
28. Alazzouzi H, Alhopuro P, Salovaara R, *et al.* SMAD4 as a prognostic marker in colorectal cancer. *Clin Cancer Res* 2005; 11: 2606-11.
29. Natsugoe S, Xiangming C, Matsumoto M, *et al.* Smad4 and transforming growth factor beta1 expression in patients with squamous cell carcinoma of the esophagus. *Clin Cancer Res* 2002; 8: 1838-42.
30. Osawa H, Shitara Y, Shoji H, *et al.* Mutation analysis of transforming growth factor beta type II receptor, Smad2, Smad3 and Smad4 in esophageal squamous cell carcinoma. *Int J Oncol* 2000; 17: 723-8.